Indisetron information

Indisetron
Clinical data
Trade names	Sinseron
Other names	N-3389
ATC code	none;
Legal status
Legal status	Rx in Japan;
Identifiers
	IUPAC name N-[(1R,5S)-3,9-Dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1H-indazole-3-carboxamide;
CAS Number	141549-75-9;
PubChem CID	178039;
ChemSpider	2302029;
UNII	89RBZ66NVC;
KEGG	D02632;
ChEBI	CHEBI:135344;
ChEMBL	ChEMBL2104994;
Chemical and physical data
Formula	C17H23N5O
Molar mass	313.405 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C[C@H]2CC(C[C@@H](C1)N2C)NC(=O)C3=NNC4=CC=CC=C43;
	InChI InChI=1S/C17H23N5O/c1-21-9-12-7-11(8-13(10-21)22(12)2)18-17(23)16-14-5-3-4-6-15(14)19-20-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,23)(H,19,20)/t11?,12-,13+; Key:MHNNVDILNTUWNS-YHWZYXNKSA-N;

Indisetron (INN; trade name Sinseron) is a drug used for prophylaxis of chemotherapy-induced nausea and vomiting. It was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2004.

Indisetron exerts its effects as a dual serotonin 5-HT₃ and 5-HT₄ receptor antagonist.^[1]^[2]

^ "Indisetron". Inxight: Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
^ Tsukagoshi S (April 2005). "[Introduction of novel anti-emetic agent, indisetron hydrochloride, developed recently in Japan]". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 32 (4): 567–73. PMID 15853230.

[1] "Indisetron". Inxight: Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.

[pmid15853230-2] Tsukagoshi S (April 2005). "[Introduction of novel anti-emetic agent, indisetron hydrochloride, developed recently in Japan]". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 32 (4): 567–73. PMID 15853230.

Indisetron information

and 2 Related for: Indisetron information

Indisetron

Isatin